ClinicalTrials.gg

Program

TYK-00540

A development code.

Its studies are mostly in Breast Neoplasms, led by TYK Medicines.

Furthest: phase 2, since Apr 11, 20253 company-led studies, 3 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
TYK Medicines33 open or runningphase 2since Apr 11, 2025Jan 18, 2024Nov 2026phase 2 · NCT07104643

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 18, 2024First study: phase 1 study in Locally Advanced or Metastatic Solid TumorsFirst studyNCT06246071 · 156 planned · China
  2. Apr 11, 2025Phase 2 study in HR-positive, HER2-negative Advanced Breast CancerNCT06950086 · 180 planned · China
  3. Jul 29, 2025Phase 2 study in mCRPCNCT07104643 · 48 planned · China

Ahead

  1. Nov 2026Primary completion: phase 2 study in mCRPCNCT07104643
  2. Dec 5, 2026Primary completion: phase 1 study in Locally Advanced or Metastatic Solid TumorsNCT06246071

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07104643mCRPC · China2Not yet recruitingNov 202648
NCT06950086HR-positive, HER2-negative Advanced Breast Cancer · China2RecruitingSep 2026180
NCT06246071Locally Advanced or Metastatic Solid Tumors · China1RecruitingDec 5, 2026156

How it is read

Names in the registry

  • “TYK-00540”, 3 entries

Codes read as this program: TYK00540.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.